Delving into the Latest Updates on Yijinsheng Capsule with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory DiseasesOther Diseases

Active Indication

FatigueLung Cancer

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization-

Active Organization

Hainan Asia Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

(1) Primary objective: To observe the tolerability and safety of this product in patients with advanced solid tumors whose condition is stable after conventional treatment through a dose escalation trial, and to recommend a safe dose for Phase II clinical trials. (2) Secondary objective: To evaluate the pharmacokinetic characteristics and dose-effect relationship (PK/PD) of this product.

Start Date14 Feb 2012

Sponsor / Collaborator

Zhejiang Yake Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with Yijinsheng Capsule

Login to view more data

100 Translational Medicine associated with Yijinsheng Capsule

Login to view more data

100 Patents (Medical) associated with Yijinsheng Capsule

Login to view more data

100 Deals associated with Yijinsheng Capsule

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fatigue	Phase 2	China	Hainan Asia Pharmaceutical Co., Ltd.	09 Mar 2020
Lung Cancer	Phase 2	China	Hainan Asia Pharmaceutical Co., Ltd.	09 Mar 2020
Advanced Malignant Solid Neoplasm	Preclinical	China	Hainan Asia Pharmaceutical Co., Ltd.	14 Feb 2012